Terms: = Lymphoma AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Clinical Outcome
4 results:
1. Germline genetic variations in methotrexate pathway are associated with pharmacokinetics, outcome, and toxicity in patients with primary central nervous system lymphoma.
Wu Z; Li Z; Qiu X; Zhong M; Ding T
Expert Rev Clin Pharmacol; 2023 Apr; 16(4):371-381. PubMed ID: 36946320
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Values of Baseline
Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229
[TBL] [Abstract] [Full Text] [Related]
3. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy.
Jewell RC; Kipps TJ; Dürig J; Griskevicius L; Stilgenbauer S; Smolej L; Mayer J; Hess G; Hernandez-Ilizaliturri FJ; Padmanabhan-Iyer S; Fang L; Goldstein N; Gorczyca M; Gupta I; Lisby S; Wierda WG;
Leuk Lymphoma; 2017 Feb; 58(2):348-356. PubMed ID: 27389174
[TBL] [Abstract] [Full Text] [Related]
4. Quantification of local tumor response to fractionated radiation therapy for non-Hodgkin lymphoma using weekly 18F-FDG PET/CT imaging.
Keller H; Goda JS; Vines DC; Lockwood G; Tsang R
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):850-8. PubMed ID: 19515502
[TBL] [Abstract] [Full Text] [Related]
